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Correction to: Journal of Investigative Dermatology (2012) 132, 1850–1859; doi:10.1038/jid.2012.63
It has come to our attention that the parental cell line used in this work was incorrectly designated. We reported that the MelRMu
human melanoma–derived cell line was used to generate sublines resistant to the BRAF inhibitor GSK2118436. The actual cell
line used in this study was the SKMel28 human melanoma–derived cell line. This has been reconfirmed using STR analyses
(StemElite ID System, Promega). This change in designation does not alter in any way the data or conclusions presented in this
report; all resistant sublines described are SKMel28-derived and the drug response data and genotype information reported for
the cell line (BRAF(V600E), EGFR (P753S), and CDK4(R24C)) are correct. The authors regret the error.
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